North Central Cancer Treatment Group (NCCTG) To Conduct Phase II Study Of Cell Therap
 

Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") announced that the North Central Cancer Treatment Group ("NCCTG") plans to conduct a Phase II study of brostallicin in combination with cisplatin in patients with metastatic triple-negative breast ("mTNBC") cancer, defined by tumors lacking expression of estrogen, progesterone receptors and without over-expression of HER2...

More...